CBD has sufficient evidence for which treatments?
Which conditions does CBD actually work for? Check out Sechat's guide with scientific evidence on epilepsy, chronic pain, anxiety, and much more.
Cannabidiol (CBD) is one of the most researched medicinal compounds of Cannabis sativa. Although it is gaining more and more space in the health and wellness debate, the scientific community and regulatory agencies are clear: the strength of evidence varies significantly depending on each health condition.
Currently, CBD has the highest level of scientific evidence for the treatment of rare and severe forms of refractory epilepsy. However, for chronic pain, sleep disorders, and anxiety disorders, studies range between moderate and preliminary evidence.
In this comprehensive guide from Sechat, you will understand exactly what science says about the efficacy of CBD for each therapeutic indication.
In this article, you will see:
- What CBD is and how it acts in the human body
- The role of the Endocannabinoid System (ECS)
- Robust evidence: severe and refractory epilepsies
- Moderate evidence: chronic pain, spasticity, and fibromyalgia
- Evidence under study: anxiety, depression, and sleep
- Neurodegenerative diseases: Alzheimer's and Parkinson's
- Safety, side effects, and drug interactions
- Regulation in Brazil and how to access legal treatment
- Scientific references
What is CBD and how does it act in the body?
The cannabidiol (CBD) is one of dozens of active substances (called cannabinoids) found in the cannabis plant. Unlike tetrahydrocannabinol (THC), CBD does not produce psychoactive effects, meaning it does not cause a "high" or alter the state of consciousness.
For this reason, CBD has become an attractive therapeutic tool for modern medicine. Scientific research indicates that the molecule has properties:
- Anticonvulsant
- Anxiolytic
- Anti-inflammatory
- Antioxidant
- Neuroprotective
However, to ensure safe and effective treatment, it is essential to distinguish which applications have robust backing and which still require more human clinical trials.
Mechanism of action: the Endocannabinoid System
The human body has its own regulatory network called the Endocannabinoid System (ECS). This system is made up of receptors (such as CB1 and CB2) spread throughout the brain, immune system, organs, and peripheral tissues, with the main goal of maintaining homeostasis (internal balance of the organism).
CBD works by modulating these receptors and directly interacting with other neurological channels, such as:
- Serotonin receptors (5-HT1A): related to mood and anxiety.
- Vanilloid receptors (TRPV1): involved in pain perception and inflammation.
It is this ability to act on multiple molecular targets that justifies the broad therapeutic potential of the phytocannabinoid.
Robust evidence: refractory epilepsy
The use of cannabidiol in treating severe, drug-resistant epilepsies represents the application with the highest level of scientific evidence.
Randomized, double-blind, placebo-controlled clinical trials have proven that CBD drastically reduces seizure frequency in conditions such as:
- Dravet Syndrome
- Lennox-Gastaut Syndrome
- Tuberous Sclerosis Complex
Systematic review studies show an average reduction of around 41% in seizures in patients treated with CBD, compared to 18% in the placebo group. These data support the approval of CBD-based medications by major regulatory agencies, such as the FDA (USA), the EMA (Europe), and Anvisa (Brazil).
Moderate evidence: chronic pain and spasticity
For pain management, evidence points to the benefit of using plant extracts, especially when conventional treatments fail:
- Spasticity in Multiple Sclerosis: Presents moderate and well-documented evidence, demonstrating improvement in muscle stiffness and patient mobility.
- Neuropathic Pain and Fibromyalgia: Research indicates that Full Spectrum extracts (which maintain CBD associated with small doses of THC and other cannabinoids) show superior efficacy compared to isolated CBD, due to the so-called entourage effect (synergy of the plant's compounds).
Although many patients report an improvement in quality of life, the medical community reinforces the need for clinical trials with larger sample sizes to standardize dosages in non-cancer chronic pain.
Evidence under study: anxiety, depression, and sleep
Despite high public demand for Cannabis-based mental health treatments, current data warrant caution:
- Anxiety: Isolated clinical trials (such as tests involving Social Anxiety Disorder) show an acute reduction in stress and anxiety. However, long-term evidence is still lacking to validate continuous use in Generalized Anxiety Disorder (GAD).
- Sleep and Insomnia: CBD can indirectly aid sleep by reducing pain and anxiety that prevent rest. However, studies focused exclusively on primary sleep disorders are still preliminary.
- Depression and PTSD: Use in depression and Post-Traumatic Stress Disorder is promising in preclinical models, but lacks consolidated clinical protocols.
Neurodegenerative diseases: Alzheimer's and Parkinson's
The neuroprotective potential of CBD has been widely investigated in neurology:
- Parkinson's Disease: Clinical evidence indicates improvement in quality of life, reduction of tremors, pain, and relief of non-motor symptoms (such as REM sleep behavior disorder and psychosis).
- Alzheimer's Disease: Preclinical studies suggest that CBD reduces neuroinflammation and aids in the clearance of amyloid-beta protein in the brain. In humans, cannabidiol has been used successfully as an adjunctive therapy to manage agitation and aggressiveness typical of advanced stages of dementia.
Safety, side effects, and drug interactions
Overall, the World Health Organization (WHO) recognizes CBD as a safe, well-tolerated substance with no potential for addiction. However, like any active compound, it can present adverse effects and interactions:
- Common side effects: Drowsiness, changes in appetite, fatigue, and diarrhea.
- Hepatic Concerns: High doses can alter liver enzymes (ALT and AST).
- Drug Interactions: CBD is metabolized by the cytochrome P450 enzyme complex in the liver. Therefore, it can alter the plasma concentration of other medications, such as blood thinners, antidepressants, and anticonvulsants.
Important: The introduction of CBD into treatment must always be accompanied by a prescribing physician for continuous dose adjustment (titration) and monitoring of interactions.
Regulation in Brazil and how to gain legal access to CBD
In Brazil, access to Cannabis-derived products is regulated by Anvisa and mandatorily requires a medical prescription:
- Pharmacies in Brazil (RDC 327/2019): It is possible to purchase Cannabis products directly at pharmacies with a type B or blue/black medical prescription (depending on the THC concentration).
- Personal Importation (RDC 660/2022): Patients can import products authorized by Anvisa by completing a simple registration on the Gov.br portal and submitting a medical prescription.
- Patient Associations: Non-profit organizations operate in the country backed by court rulings to supply Cannabis oil at cost price to their members.
Follow the latest news on Sechat
Cannabis medicine is advancing at a rapid pace in Brazil and worldwide. Sechat is your go-to news portal for regulations, business, health, and scientific advances in the medical Cannabis market.
Want to know more about treatments and regulation?
Scientific references
- Fiocruz. Technical Note: Current state of evidence on the therapeutic uses of cannabinoids. 2023.
- Federal Council of Medicine (CFM). Cannabidiol: motives and evidence.
- World Health Organization (WHO). Cannabidiol (CBD) Critical Review Report.
- Devinsky, O., et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. The New England Journal of Medicine (NEJM).
- National Health Surveillance Agency (Anvisa). RDC No. 327/2019 and RDC No. 660/2022.
Reviewed by Sechat Editorial Team